Preclinical data have showed a strong antiproliferative activity of this compound in a panel of human NSCLC cell lines harbouring FGFR aberrations and tumour growth inhibition in a gastric cancer FGFR2-amplified mouse xenograft model [94,114]. The gene discussed is FGFR2; the disease is non-small cell lung carcinoma.